These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29477368)

  • 1. Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate.
    Eze C; Manapov F; Gratzke C; Schmidt-Hegemann NS; Jung A; Kirchner T; Heinemann V; Stief CG; Belka C; Boeck S
    Eur J Cancer; 2018 May; 95():109-111. PubMed ID: 29477368
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lung Adenosquamous Cell Carcinoma in which the Administration of Nivolumab Became Untenable due to Bleeding from Small Intestine Metastasis].
    Motono N; Iwai S; Funasaki A; Sekimura A; Usuda K; Uramoto H
    Kyobu Geka; 2018 Oct; 71(11):948-951. PubMed ID: 30310008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab plus ipilimumab in metastatic colorectal cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
    Beulque Y; Deleu AL; Punie K; De Wever L; Baldewijns M; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Oct; 17(5):e909-e912. PubMed ID: 31378579
    [No Abstract]   [Full Text] [Related]  

  • 5. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
    Hida T
    Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma.
    Siegel CH; Finn RS; Ho MG
    Mayo Clin Proc; 2018 Apr; 93(4):540-541. PubMed ID: 29622100
    [No Abstract]   [Full Text] [Related]  

  • 7. Nivolumab for the treatment of urothelial cancers.
    Teo MY; Rosenberg JE
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):215-221. PubMed ID: 29363363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors May Cause Pseudoprogression and Dose-Limiting Side Effects.
    Wiley K
    ONS Connect; 2016 Jul; 31(7):24. PubMed ID: 30549937
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis.
    Kubo K; Kato M; Mabe K
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):A35-A36. PubMed ID: 28351793
    [No Abstract]   [Full Text] [Related]  

  • 11. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
    Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
    PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
    Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
    Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab.
    Asano R; Shinoda K; Tsuda R; Hounoki H; Kawataka M; Makino T; Imura J; Hamaguchi Y; Tobe K
    Rheumatology (Oxford); 2021 Jun; 60(6):e197-e199. PubMed ID: 33367923
    [No Abstract]   [Full Text] [Related]  

  • 15. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
    Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
    J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
    [No Abstract]   [Full Text] [Related]  

  • 16. Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease.
    Day F; Sridharan S; Johnson C; Quah GT; Mallesara G; Kumar M; Poulter AL; Morrison A; van der Westhuizen A; Fraser A; Oldmeadow C; Martin J
    Asia Pac J Clin Oncol; 2024 Jun; 20(3):416-422. PubMed ID: 38512856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
    Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
    J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
    [No Abstract]   [Full Text] [Related]  

  • 18. Nivolumab-Induced Colitis Treated by Infliximab.
    Yanai S; Nakamura S; Matsumoto T
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):e80-e81. PubMed ID: 27664866
    [No Abstract]   [Full Text] [Related]  

  • 19. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
    Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
    Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histoseminar on inflammatory bowel diseases (IBD): Case n
    Fléjou JF
    Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.